About the Speaker

Dr. Hsiao-Mei Lu, is the Vice President of Bioinformatics & Computational Biology in Ambry Genetics, one of the largest molecular diagnostics company in USA. She leads a team of scientists, statisticians, and computational biologists and has developed numerous next generation sequencing pipelines and variant assessment schemes for clinical diagnostics in cancer, cardiological, and neurological diseases. In 2011, Dr. Lu joined Ambry Genetics and successfully built clinical bioinformatics pipelines for whole exome sequencing and clinical diagnostics in hereditary and somatic cancer, cardiological and neurological diseases. She leads a team of scientists, statistical geneticists, and computational biologists and has developed numerous computational tools and conducted clinical research projects. Dr. Lu is also an active scientist in human genetics, machine learning, data mining, and mathematical modeling. Dr. Lu received her doctor's degree in Bioinformatics from University of Illinois at Chicago, and continued her postdoctoral research in University of California, Irvine. In March 2016, New York Times reported the release of Ambry's 10,000 cancer database, which was curated and analyzed with her pipeline and discovered more than 100 novel cancer genes.

About Ambry Genetics

Ambry Genetics is a privately-held healthcare company with the most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases. Since 1999, Ambry has tested approximately half a million patient samples benefiting 90% of all U.S. patients covered by public and private insurers. Ambry is dedicated to scientific collaboration by offering its rapidly growing AmbryShare database of anonymized patient records free to the global medical research community to fulfill the promise of the human genome to cure or manage all human disease. Ambry is dedicated to the belief that human health should not be patented or owned, and genomic data should be freely shared so we can try to cure all disease.